- Voluntary agreement meets the President’s four requests while also protecting the U.S. ecosystem responsible for America’s leadership in delivering medical breakthroughs
- Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer’s ability to expand investment in U.S.-based innovation and return manufacturing to the U.S.
- Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology
- Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today
Author Archive: AZBio
PhRMA Announces Major Actions as Part of Industry’s Commitment to American Patients and Workers
WASHINGTON, D.C. (September 29, 2025) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced three major actions as part of the biopharmaceutical industry’s commitment to American patients and workers.
PhRMA member companies are making historic investments in U.S.-based manufacturing and infrastructure, providing financial assistance to millions of insured and underinsured patients who have been failed by a broken health insurance system, and announcing a new website that will simplify access to manufacturer direct purchase and patient assistance resources. Continue reading
A new era in ASU X-ray science officially begins
First X-ray machine’s commissioning milestone marks start of research phase for one-of-a-kind labContinue reading
The Value of Managing Valley Fever for Arizona Stakeholders
Managing Valley fever starts with awareness. Since there’s no surefire way to avoid getting Valley fever in Arizona, knowledge is everyone’s best defense — but awareness needs a community effort. Continue reading
Governor Katie Hobbs Appoints Virginia “Ginny” Rountree to lead AHCCCS
Governor Katie Hobbs Appoints Virginia “Ginny” Rountree to lead AHCCCSContinue reading
Administration Announces a 100 Percent Potential Tariff on Branded or Patented Pharmaceuticals
President Trump posted the following on Truth Social on Thursday, September 25, 2025: “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. “IS BUILDING” will be defined as, “breaking ground” and/or “under construction.” There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. Thank you for your attention to this matter!” Source: https://truthsocial.com/@realDonaldTrump/115267512131958759Continue reading
Online Resource Spotlights A New Era of Biopharmaceutical Innovation
The biopharmaceutical industry is on the brink of unprecedented breakthroughs, with the potential to revolutionize health care, reduce the burden of disease and create a healthier future for all. Innovation.org puts biopharmaceutical innovation in the spotlight.
Next up for Section 232 Investigations – Medtech
The US Commerce Department disclosed on September 24, 2025 that new “Section 232” investigations into the import of personal protective equipment, medical items, robotics and industrial machinery were opened on September 2, 2025 but not previously disclosed.Continue reading
MiiHealth AI to Collaborate with one of the leading Health Systems in the United States to advance DAINA, its AI Agent for Streamlining Patient Intake
Phoenix, Ariz., MiiHealth AI, an emerging leader in agentic AI for healthcare, has announced it has entered into a know-how agreement with Mayo Clinic. This collaboration aims to revolutionize patient intake, streamline provider workflows, and enhance care quality.Continue reading